Please wait while the formulary information is being retrieved.
Drug overview for CEFIXIME (cefixime):
Generic name: CEFIXIME (sef-IX-eem)
Drug class: Beta-Lactams
Therapeutic class: Anti-Infective Agents
Cefixime is a semisynthetic, third generation cephalosporin antibiotic.
Cefixime is used orally in adult and pediatric patients for the treatment of acute otitis media caused by susceptible bacteria; pharyngitis and tonsillitis caused by Streptococcus pyogenes (group A beta-hemolytic streptococci); respiratory tract infections (e.g., acute exacerbations of chronic bronchitis, pneumonia+) caused by susceptible bacteria; and uncomplicated urinary tract infections caused by susceptible bacteria. The drug also has been used for the treatment of gonorrhea and infections caused by susceptible Salmonella+ or Shigella+. Because cefixime has a long serum half-life and can be administered once or twice daily, some clinicians suggest that the drug may be particularly useful when patient compliance is a concern (e.g., in the treatment of otitis media).
Although cefixime is an effective alternative to other anti-infective agents for the treatment of many infections, the drug offers no clear advantage (except for a convenient dosage regimen) over other equally effective, less expensive anti-infectives available for the treatment of uncomplicated urinary tract infections or upper and lower respiratory tract infections. In addition, use of cefixime as empiric therapy in some infections (e.g., urinary tract infections, respiratory tract infections, soft tissue infections) is limited by its spectrum of activity since the drug is inactive against staphylococci, enterococci, and Pseudomonas aeruginosa. Because cefixime is inactive against most anaerobic bacteria, the drug is ineffective in and should not be used alone if a mixed aerobic-anaerobic bacterial infection is suspected.
Prior to initiation of cefixime therapy, appropriate specimens should be obtained for identification of the causative organism(s) and in vitro susceptibility tests. Cefixime therapy may be started pending results of susceptibility tests, but should be discontinued and other appropriate anti-infective therapy substituted if the organism is found to be resistant to cefixime.
Generic name: CEFIXIME (sef-IX-eem)
Drug class: Beta-Lactams
Therapeutic class: Anti-Infective Agents
Cefixime is a semisynthetic, third generation cephalosporin antibiotic.
Cefixime is used orally in adult and pediatric patients for the treatment of acute otitis media caused by susceptible bacteria; pharyngitis and tonsillitis caused by Streptococcus pyogenes (group A beta-hemolytic streptococci); respiratory tract infections (e.g., acute exacerbations of chronic bronchitis, pneumonia+) caused by susceptible bacteria; and uncomplicated urinary tract infections caused by susceptible bacteria. The drug also has been used for the treatment of gonorrhea and infections caused by susceptible Salmonella+ or Shigella+. Because cefixime has a long serum half-life and can be administered once or twice daily, some clinicians suggest that the drug may be particularly useful when patient compliance is a concern (e.g., in the treatment of otitis media).
Although cefixime is an effective alternative to other anti-infective agents for the treatment of many infections, the drug offers no clear advantage (except for a convenient dosage regimen) over other equally effective, less expensive anti-infectives available for the treatment of uncomplicated urinary tract infections or upper and lower respiratory tract infections. In addition, use of cefixime as empiric therapy in some infections (e.g., urinary tract infections, respiratory tract infections, soft tissue infections) is limited by its spectrum of activity since the drug is inactive against staphylococci, enterococci, and Pseudomonas aeruginosa. Because cefixime is inactive against most anaerobic bacteria, the drug is ineffective in and should not be used alone if a mixed aerobic-anaerobic bacterial infection is suspected.
Prior to initiation of cefixime therapy, appropriate specimens should be obtained for identification of the causative organism(s) and in vitro susceptibility tests. Cefixime therapy may be started pending results of susceptibility tests, but should be discontinued and other appropriate anti-infective therapy substituted if the organism is found to be resistant to cefixime.
DRUG IMAGES
CEFIXIME 400 MG CAPSULE
The following indications for CEFIXIME (cefixime) have been approved by the FDA:
Indications:
E. coli urinary tract infection
Haemophilus influenzae acute otitis media
Haemophilus influenzae bronchitis
Moraxella catarrhalis acute otitis media
Pharyngitis due to Streptococcus pyogenes
Proteus urinary tract infection
Streptococcus acute otitis media
Streptococcus pneumoniae bronchitis
Tonsillitis due to Streptococcus pyogenes
Professional Synonyms:
Acute otitis media due to H. flu
Acute otitis media due to Haemophilus influenzae
Acute otitis media due to Hemophilus influenzae
Acute otitis media due to influenza Bacillus
Acute otitis media due to Moraxella catarrhalis
Acute otitis media due to Pfeiffer's Bacillus
Acute otitis media due to Streptococcus species
Bronchitis due to Diplococcus pneumoniae
Bronchitis due to Fraenkel's Pneumococcus
Bronchitis due to Fraenkel-Weichselbaum Pneumococcus
Bronchitis due to H. flu
Bronchitis due to H. influenzae
Bronchitis due to Haemophilus influenzae
Bronchitis due to Hemophilus influenzae
Bronchitis due to influenzae Bacillus
Bronchitis due to Pfeiffer's Bacillus
Bronchitis due to Pneumococcus
Bronchitis due to Pneumonococcus
Bronchitis due to Streptococcus pneumoniae
E. coli UTI
Epidemic sore throat
Pharyngitis due to group A beta-hemolytic streptococci
Pharyngitis due to Streptococcus epidemicus
Septic sore throat
Streptococcal pharyngitis
Streptococcus pyogenes tonsillitis
Urinary tract infection due to Escherichia coli
Urinary tract infection due to Proteus species
UTI due to Proteus species
Indications:
E. coli urinary tract infection
Haemophilus influenzae acute otitis media
Haemophilus influenzae bronchitis
Moraxella catarrhalis acute otitis media
Pharyngitis due to Streptococcus pyogenes
Proteus urinary tract infection
Streptococcus acute otitis media
Streptococcus pneumoniae bronchitis
Tonsillitis due to Streptococcus pyogenes
Professional Synonyms:
Acute otitis media due to H. flu
Acute otitis media due to Haemophilus influenzae
Acute otitis media due to Hemophilus influenzae
Acute otitis media due to influenza Bacillus
Acute otitis media due to Moraxella catarrhalis
Acute otitis media due to Pfeiffer's Bacillus
Acute otitis media due to Streptococcus species
Bronchitis due to Diplococcus pneumoniae
Bronchitis due to Fraenkel's Pneumococcus
Bronchitis due to Fraenkel-Weichselbaum Pneumococcus
Bronchitis due to H. flu
Bronchitis due to H. influenzae
Bronchitis due to Haemophilus influenzae
Bronchitis due to Hemophilus influenzae
Bronchitis due to influenzae Bacillus
Bronchitis due to Pfeiffer's Bacillus
Bronchitis due to Pneumococcus
Bronchitis due to Pneumonococcus
Bronchitis due to Streptococcus pneumoniae
E. coli UTI
Epidemic sore throat
Pharyngitis due to group A beta-hemolytic streptococci
Pharyngitis due to Streptococcus epidemicus
Septic sore throat
Streptococcal pharyngitis
Streptococcus pyogenes tonsillitis
Urinary tract infection due to Escherichia coli
Urinary tract infection due to Proteus species
UTI due to Proteus species
The following dosing information is available for CEFIXIME (cefixime):
Cefixime is commercially available as the trihydrate; potency of the drug is expressed in terms of cefixime (the free acid), calculated on the anhydrous basis.
Cefixime may be administered once or twice daily. Once- and twice-daily regimens reportedly are similarly effective for the treatment of otitis media, tonsillitis, or uncomplicated urinary tract infections. Relative efficacy of the 2 regimens has not been evaluated in other infections, and some clinicians suggest that twice-daily dosing may be preferable for the treatment of some lower respiratory tract infections or for complicated urinary tract infections+.
Results of most studies indicate that the incidence of GI effects is similar with once- and twice-daily regimens. (See Cautions: GI Effects.)
Capsules containing 400 mg of cefixime are bioequivalent to conventional tablets containing 400 mg of the drug when administered under fasting conditions.
Cefixime chewable tablets are bioequivalent to cefixime oral suspension.
Cefixime conventional tablets and oral suspension are not bioequivalent. (See Pharmacokinetics: Absorption.)
Children older than 12 years of age or those weighing more than 45 kg may receive the usual adult dosage of cefixime.
For pediatric patients beyond the neonatal period, the American Academy of Pediatrics (AAP) recommends a cefixime dosage of 8 mg/kg daily given in 1 or 2 divided doses for the treatment of mild to moderate infections. The AAP states that cefixime is inappropriate for the treatment of severe infections.
The oral suspension containing 100 mg of cefixime per 5 mL is the preferred preparation for use in children weighing 5-7.5 kg; oral suspensions containing 100 or 200 mg of cefixime per 5 mL are the preferred preparations in those weighing 7.6-10 kg.
Cefixime chewable tablets are not recommended in children weighing less than 10 kg.
In patients with creatinine clearances less than 60 mL/minute, dose and/or frequency of administration of cefixime should be modified in response to the degree of renal impairment. The manufacturer recommends that adults with creatinine clearances of 21-59 mL/minute and those undergoing hemodialysis receive a cefixime dosage of 260 mg daily administered as oral suspension, preferably as oral suspension containing 200 or 500 mg of cefixime per 5 mL; cefixime conventional tablets and chewable tablets are not recommended in these patients. The manufacturer also recommends that adults with creatinine clearances of 20 mL/minute or less and those undergoing continuous peritoneal dialysis receive a cefixime dosage of 200 mg daily as conventional tablets or chewable tablets, 172 mg daily as oral suspension containing 100 mg/5 mL, 176 mg daily as oral suspension containing 200 mg/5 mL, or 180 mg daily as oral suspension containing 500 mg/5 mL.
Because cefixime is not substantially removed by hemodialysis or peritoneal dialysis, additional supplemental doses of the drug are not necessary during or after either procedure.
Modification of the usual dosage of cefixime is not necessary in geriatric adults based on age, but may be required because of age-related decreases in renal function. (See Dosage and Administration: Dosage in Renal Impairment.)
Cefixime may be administered once or twice daily. Once- and twice-daily regimens reportedly are similarly effective for the treatment of otitis media, tonsillitis, or uncomplicated urinary tract infections. Relative efficacy of the 2 regimens has not been evaluated in other infections, and some clinicians suggest that twice-daily dosing may be preferable for the treatment of some lower respiratory tract infections or for complicated urinary tract infections+.
Results of most studies indicate that the incidence of GI effects is similar with once- and twice-daily regimens. (See Cautions: GI Effects.)
Capsules containing 400 mg of cefixime are bioequivalent to conventional tablets containing 400 mg of the drug when administered under fasting conditions.
Cefixime chewable tablets are bioequivalent to cefixime oral suspension.
Cefixime conventional tablets and oral suspension are not bioequivalent. (See Pharmacokinetics: Absorption.)
Children older than 12 years of age or those weighing more than 45 kg may receive the usual adult dosage of cefixime.
For pediatric patients beyond the neonatal period, the American Academy of Pediatrics (AAP) recommends a cefixime dosage of 8 mg/kg daily given in 1 or 2 divided doses for the treatment of mild to moderate infections. The AAP states that cefixime is inappropriate for the treatment of severe infections.
The oral suspension containing 100 mg of cefixime per 5 mL is the preferred preparation for use in children weighing 5-7.5 kg; oral suspensions containing 100 or 200 mg of cefixime per 5 mL are the preferred preparations in those weighing 7.6-10 kg.
Cefixime chewable tablets are not recommended in children weighing less than 10 kg.
In patients with creatinine clearances less than 60 mL/minute, dose and/or frequency of administration of cefixime should be modified in response to the degree of renal impairment. The manufacturer recommends that adults with creatinine clearances of 21-59 mL/minute and those undergoing hemodialysis receive a cefixime dosage of 260 mg daily administered as oral suspension, preferably as oral suspension containing 200 or 500 mg of cefixime per 5 mL; cefixime conventional tablets and chewable tablets are not recommended in these patients. The manufacturer also recommends that adults with creatinine clearances of 20 mL/minute or less and those undergoing continuous peritoneal dialysis receive a cefixime dosage of 200 mg daily as conventional tablets or chewable tablets, 172 mg daily as oral suspension containing 100 mg/5 mL, 176 mg daily as oral suspension containing 200 mg/5 mL, or 180 mg daily as oral suspension containing 500 mg/5 mL.
Because cefixime is not substantially removed by hemodialysis or peritoneal dialysis, additional supplemental doses of the drug are not necessary during or after either procedure.
Modification of the usual dosage of cefixime is not necessary in geriatric adults based on age, but may be required because of age-related decreases in renal function. (See Dosage and Administration: Dosage in Renal Impairment.)
No enhanced Administration information available for this drug.
| DRUG LABEL | DOSING TYPE | DOSING INSTRUCTIONS |
|---|---|---|
| CEFIXIME 400 MG CAPSULE | Maintenance | Adults take 1 capsule (400 mg) by oral route once daily |
| DRUG LABEL | DOSING TYPE | DOSING INSTRUCTIONS |
|---|---|---|
| CEFIXIME 400 MG CAPSULE | Maintenance | Adults take 1 capsule (400 mg) by oral route once daily |
The following drug interaction information is available for CEFIXIME (cefixime):
There are 1 contraindications.
These drug combinations generally should not be dispensed or administered to the same patient. A manufacturer label warning that indicates the contraindication warrants inclusion of a drug combination in this category, regardless of clinical evidence or lack of clinical evidence to support the contraindication.
| Drug Interaction | Drug Names |
|---|---|
| Live Typhoid Vaccine/Antimicrobials SEVERITY LEVEL: 1-Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient. MECHANISM OF ACTION: The antimicrobial may be active against the organism in the live-vaccine. Antimicrobial therapy may prevent the vaccine organism from replicating enough to trigger an immune response.(1) CLINICAL EFFECTS: Vaccination may be ineffective. PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Do not give oral typhoid vaccine until 72 hours after the last dose of antimicrobial. If possible, to optimize vaccine effectiveness, do not start antibacterial drugs for 72 hours after the last dose of oral typhoid vaccine. A longer interval should be considered for long-acting antimicrobials, such as azithromycin.(3) DISCUSSION: Because antimicrobial therapy may prevent sufficient vaccine-organism replication to generate an immune response, the manufacturer of live-attenuated typhoid vaccine and the Centers for Disease Control (CDC) state that the vaccine should not be administered to patients receiving antimicrobial therapy.(1-3) |
VIVOTIF |
There are 1 severe interactions.
These drug interactions can produce serious consequences in most patients. Actions required for severe interactions include, but are not limited to, discontinuing one or both agents, adjusting dosage, altering administration scheduling, and providing additional patient monitoring. Review the full interaction monograph for more information.
| Drug Interaction | Drug Names |
|---|---|
| Fecal Microbiota Spores/Antibiotics SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Fecal microbiota spores is a suspension of live bacterial spores, which may be compromised by concurrent use of antibiotics.(1) CLINICAL EFFECTS: Antibiotics may decrease the effectiveness of fecal microbiota spores.(1) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Antibiotics should not be used concurrently with fecal microbiota spores. Antibacterial treatment should be completed for 2 to 4 days before initiating treatment with fecal microbiota spores.(1) DISCUSSION: Antibiotics may compromise the effectiveness of fecal microbiota spores. |
VOWST |
There are 0 moderate interactions.
The following contraindication information is available for CEFIXIME (cefixime):
Drug contraindication overview.
No enhanced Contraindications information available for this drug.
No enhanced Contraindications information available for this drug.
There are 0 contraindications.
There are 5 severe contraindications.
Adequate patient monitoring is recommended for safer drug use.
| Severe List |
|---|
| Chronic kidney disease stage 3A (moderate) GFR 45-59 ml/min |
| Chronic kidney disease stage 3B (moderate) GFR 30-44 ml/min |
| Chronic kidney disease stage 4 (severe) GFR 15-29 ml/min |
| Chronic kidney disease stage 5 (failure) GFr<15 ml/min |
| Clostridioides difficile infection |
There are 0 moderate contraindications.
The following adverse reaction information is available for CEFIXIME (cefixime):
Adverse reaction overview.
No enhanced Common Adverse Effects information available for this drug.
No enhanced Common Adverse Effects information available for this drug.
There are 28 severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
| None. | None. |
| Rare/Very Rare |
|---|
|
Abnormal hepatic function tests Acute generalized exanthematous pustulosis Agranulocytosis Anaphylaxis Angioedema Clostridioides difficile infection DRESS syndrome Drug fever Eosinophilia Erythema multiforme Hemolytic anemia Hepatitis Hyperbilirubinemia Hypoprothrombinemia Jaundice Kidney disease with reduction in glomerular filtration rate (GFr) Leukopenia Neutropenic disorder Pancytopenia Pruritus of skin Renal failure Seizure disorder Serum sickness Skin rash Stevens-johnson syndrome Thrombocytopenic disorder Thrombocytosis Toxic epidermal necrolysis |
There are 14 less severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
|
Acute abdominal pain Diarrhea Dyspepsia Loose stools Nausea Vomiting |
Candidiasis Dizziness Flatulence Headache disorder Vaginitis |
| Rare/Very Rare |
|---|
|
Facial edema Genital organ pruritus Urticaria |
The following precautions are available for CEFIXIME (cefixime):
No enhanced Pediatric Use information available for this drug.
Contraindicated
Severe Precaution
Management or Monitoring Precaution
Contraindicated
| None |
Severe Precaution
| None |
Management or Monitoring Precaution
| None |
Reproduction studies in mice and rats using oral cefixime dosages up to 40 times the usual human dosage have not revealed evidence of harm to the fetus. There are no adequate and controlled studies to date using cefixime in pregnant women, and the drug should be used during pregnancy only when clearly needed. Use of cefixime during labor and delivery has not been studied to date, and the drug should be used in these circumstances only when clearly needed.
Cefixime is distributed into milk in rats. Although the drug reportedly was not detected in milk following a single dose in lactating women in one study (see Pharmacokinetics: Distribution), it is not known whether cefixime is distributed into milk in humans. Therefore, consideration should be given to temporarily discontinuing nursing during therapy with the drug.
No enhanced Geriatric Use information available for this drug.
The following prioritized warning is available for CEFIXIME (cefixime):
No warning message for this drug.
No warning message for this drug.
The following icd codes are available for CEFIXIME (cefixime)'s list of indications:
| E. coli urinary tract infection | |
| B96.2 | Escherichia coli [e. coli ] as the cause of diseases classified elsewhere |
| B96.20 | Unspecified escherichia coli [e. coli] as the cause of diseases classified elsewhere |
| B96.29 | Other escherichia coli [e. coli] as the cause of diseases classified elsewhere |
| N30.0 | Acute cystitis |
| N30.00 | Acute cystitis without hematuria |
| N30.01 | Acute cystitis with hematuria |
| N30.9 | Cystitis, unspecified |
| N30.90 | Cystitis, unspecified without hematuria |
| N30.91 | Cystitis, unspecified with hematuria |
| N39.0 | Urinary tract infection, site not specified |
| O23.0 | Infections of kidney in pregnancy |
| O23.00 | Infections of kidney in pregnancy, unspecified trimester |
| O23.01 | Infections of kidney in pregnancy, first trimester |
| O23.02 | Infections of kidney in pregnancy, second trimester |
| O23.03 | Infections of kidney in pregnancy, third trimester |
| O23.1 | Infections of bladder in pregnancy |
| O23.10 | Infections of bladder in pregnancy, unspecified trimester |
| O23.11 | Infections of bladder in pregnancy, first trimester |
| O23.12 | Infections of bladder in pregnancy, second trimester |
| O23.13 | Infections of bladder in pregnancy, third trimester |
| O23.2 | Infections of urethra in pregnancy |
| O23.20 | Infections of urethra in pregnancy, unspecified trimester |
| O23.21 | Infections of urethra in pregnancy, first trimester |
| O23.22 | Infections of urethra in pregnancy, second trimester |
| O23.23 | Infections of urethra in pregnancy, third trimester |
| O23.3 | Infections of other parts of urinary tract in pregnancy |
| O23.30 | Infections of other parts of urinary tract in pregnancy, unspecified trimester |
| O23.31 | Infections of other parts of urinary tract in pregnancy, first trimester |
| O23.32 | Infections of other parts of urinary tract in pregnancy, second trimester |
| O23.33 | Infections of other parts of urinary tract in pregnancy, third trimester |
| O23.4 | Unspecified infection of urinary tract in pregnancy |
| O23.40 | Unspecified infection of urinary tract in pregnancy, unspecified trimester |
| O23.41 | Unspecified infection of urinary tract in pregnancy, first trimester |
| O23.42 | Unspecified infection of urinary tract in pregnancy, second trimester |
| O23.43 | Unspecified infection of urinary tract in pregnancy, third trimester |
| O23.9 | Unspecified genitourinary tract infection in pregnancy |
| O23.90 | Unspecified genitourinary tract infection in pregnancy, unspecified trimester |
| O23.91 | Unspecified genitourinary tract infection in pregnancy, first trimester |
| O23.92 | Unspecified genitourinary tract infection in pregnancy, second trimester |
| O23.93 | Unspecified genitourinary tract infection in pregnancy, third trimester |
| Haemophilus influenzae acute otitis media | |
| B96.3 | Hemophilus influenzae [h. influenzae] as the cause of diseases classified elsewhere |
| H66.0 | Acute suppurative otitis media |
| H66.00 | Acute suppurative otitis media without spontaneous rupture of ear drum |
| H66.001 | Acute suppurative otitis media without spontaneous rupture of ear drum, right ear |
| H66.002 | Acute suppurative otitis media without spontaneous rupture of ear drum, left ear |
| H66.003 | Acute suppurative otitis media without spontaneous rupture of ear drum, bilateral |
| H66.004 | Acute suppurative otitis media without spontaneous rupture of ear drum, recurrent, right ear |
| H66.005 | Acute suppurative otitis media without spontaneous rupture of ear drum, recurrent, left ear |
| H66.006 | Acute suppurative otitis media without spontaneous rupture of ear drum, recurrent, bilateral |
| H66.007 | Acute suppurative otitis media without spontaneous rupture of ear drum, recurrent, unspecified ear |
| H66.009 | Acute suppurative otitis media without spontaneous rupture of ear drum, unspecified ear |
| H66.01 | Acute suppurative otitis media with spontaneous rupture of ear drum |
| H66.011 | Acute suppurative otitis media with spontaneous rupture of ear drum, right ear |
| H66.012 | Acute suppurative otitis media with spontaneous rupture of ear drum, left ear |
| H66.013 | Acute suppurative otitis media with spontaneous rupture of ear drum, bilateral |
| H66.014 | Acute suppurative otitis media with spontaneous rupture of ear drum, recurrent, right ear |
| H66.015 | Acute suppurative otitis media with spontaneous rupture of ear drum, recurrent, left ear |
| H66.016 | Acute suppurative otitis media with spontaneous rupture of ear drum, recurrent, bilateral |
| H66.017 | Acute suppurative otitis media with spontaneous rupture of ear drum, recurrent, unspecified ear |
| H66.019 | Acute suppurative otitis media with spontaneous rupture of ear drum, unspecified ear |
| H66.9 | Otitis media, unspecified |
| H66.90 | Otitis media, unspecified, unspecified ear |
| H66.91 | Otitis media, unspecified, right ear |
| H66.92 | Otitis media, unspecified, left ear |
| H66.93 | Otitis media, unspecified, bilateral |
| Haemophilus influenzae bronchitis | |
| J20.1 | Acute bronchitis due to hemophilus influenzae |
| Moraxella catarrhalis acute otitis media | |
| B96.89 | Other specified bacterial agents as the cause of diseases classified elsewhere |
| H66.0 | Acute suppurative otitis media |
| H66.00 | Acute suppurative otitis media without spontaneous rupture of ear drum |
| H66.001 | Acute suppurative otitis media without spontaneous rupture of ear drum, right ear |
| H66.002 | Acute suppurative otitis media without spontaneous rupture of ear drum, left ear |
| H66.003 | Acute suppurative otitis media without spontaneous rupture of ear drum, bilateral |
| H66.004 | Acute suppurative otitis media without spontaneous rupture of ear drum, recurrent, right ear |
| H66.005 | Acute suppurative otitis media without spontaneous rupture of ear drum, recurrent, left ear |
| H66.006 | Acute suppurative otitis media without spontaneous rupture of ear drum, recurrent, bilateral |
| H66.007 | Acute suppurative otitis media without spontaneous rupture of ear drum, recurrent, unspecified ear |
| H66.009 | Acute suppurative otitis media without spontaneous rupture of ear drum, unspecified ear |
| H66.01 | Acute suppurative otitis media with spontaneous rupture of ear drum |
| H66.011 | Acute suppurative otitis media with spontaneous rupture of ear drum, right ear |
| H66.012 | Acute suppurative otitis media with spontaneous rupture of ear drum, left ear |
| H66.013 | Acute suppurative otitis media with spontaneous rupture of ear drum, bilateral |
| H66.014 | Acute suppurative otitis media with spontaneous rupture of ear drum, recurrent, right ear |
| H66.015 | Acute suppurative otitis media with spontaneous rupture of ear drum, recurrent, left ear |
| H66.016 | Acute suppurative otitis media with spontaneous rupture of ear drum, recurrent, bilateral |
| H66.017 | Acute suppurative otitis media with spontaneous rupture of ear drum, recurrent, unspecified ear |
| H66.019 | Acute suppurative otitis media with spontaneous rupture of ear drum, unspecified ear |
| H66.4 | Suppurative otitis media, unspecified |
| H66.40 | Suppurative otitis media, unspecified, unspecified ear |
| H66.41 | Suppurative otitis media, unspecified, right ear |
| H66.42 | Suppurative otitis media, unspecified, left ear |
| H66.43 | Suppurative otitis media, unspecified, bilateral |
| H66.9 | Otitis media, unspecified |
| H66.91 | Otitis media, unspecified, right ear |
| H66.92 | Otitis media, unspecified, left ear |
| H66.93 | Otitis media, unspecified, bilateral |
| Pharyngitis due to streptococcus pyogenes | |
| J02.0 | Streptococcal pharyngitis |
| Proteus urinary tract infection | |
| B96.4 | Proteus (mirabilis) (morganii) as the cause of diseases classified elsewhere |
| N30.0 | Acute cystitis |
| N30.00 | Acute cystitis without hematuria |
| N30.01 | Acute cystitis with hematuria |
| N30.9 | Cystitis, unspecified |
| N30.90 | Cystitis, unspecified without hematuria |
| N30.91 | Cystitis, unspecified with hematuria |
| N39.0 | Urinary tract infection, site not specified |
| O23.0 | Infections of kidney in pregnancy |
| O23.00 | Infections of kidney in pregnancy, unspecified trimester |
| O23.01 | Infections of kidney in pregnancy, first trimester |
| O23.02 | Infections of kidney in pregnancy, second trimester |
| O23.03 | Infections of kidney in pregnancy, third trimester |
| O23.1 | Infections of bladder in pregnancy |
| O23.10 | Infections of bladder in pregnancy, unspecified trimester |
| O23.11 | Infections of bladder in pregnancy, first trimester |
| O23.12 | Infections of bladder in pregnancy, second trimester |
| O23.13 | Infections of bladder in pregnancy, third trimester |
| O23.2 | Infections of urethra in pregnancy |
| O23.20 | Infections of urethra in pregnancy, unspecified trimester |
| O23.21 | Infections of urethra in pregnancy, first trimester |
| O23.22 | Infections of urethra in pregnancy, second trimester |
| O23.23 | Infections of urethra in pregnancy, third trimester |
| O23.3 | Infections of other parts of urinary tract in pregnancy |
| O23.30 | Infections of other parts of urinary tract in pregnancy, unspecified trimester |
| O23.31 | Infections of other parts of urinary tract in pregnancy, first trimester |
| O23.32 | Infections of other parts of urinary tract in pregnancy, second trimester |
| O23.33 | Infections of other parts of urinary tract in pregnancy, third trimester |
| O23.4 | Unspecified infection of urinary tract in pregnancy |
| O23.40 | Unspecified infection of urinary tract in pregnancy, unspecified trimester |
| O23.41 | Unspecified infection of urinary tract in pregnancy, first trimester |
| O23.42 | Unspecified infection of urinary tract in pregnancy, second trimester |
| O23.43 | Unspecified infection of urinary tract in pregnancy, third trimester |
| O23.9 | Unspecified genitourinary tract infection in pregnancy |
| O23.90 | Unspecified genitourinary tract infection in pregnancy, unspecified trimester |
| O23.91 | Unspecified genitourinary tract infection in pregnancy, first trimester |
| O23.92 | Unspecified genitourinary tract infection in pregnancy, second trimester |
| O23.93 | Unspecified genitourinary tract infection in pregnancy, third trimester |
| Streptococcus acute otitis media | |
| B95.0 | Streptococcus, group a, as the cause of diseases classified elsewhere |
| B95.4 | Other streptococcus as the cause of diseases classified elsewhere |
| B95.5 | Unspecified streptococcus as the cause of diseases classified elsewhere |
| H66.0 | Acute suppurative otitis media |
| H66.00 | Acute suppurative otitis media without spontaneous rupture of ear drum |
| H66.001 | Acute suppurative otitis media without spontaneous rupture of ear drum, right ear |
| H66.002 | Acute suppurative otitis media without spontaneous rupture of ear drum, left ear |
| H66.003 | Acute suppurative otitis media without spontaneous rupture of ear drum, bilateral |
| H66.004 | Acute suppurative otitis media without spontaneous rupture of ear drum, recurrent, right ear |
| H66.005 | Acute suppurative otitis media without spontaneous rupture of ear drum, recurrent, left ear |
| H66.006 | Acute suppurative otitis media without spontaneous rupture of ear drum, recurrent, bilateral |
| H66.007 | Acute suppurative otitis media without spontaneous rupture of ear drum, recurrent, unspecified ear |
| H66.009 | Acute suppurative otitis media without spontaneous rupture of ear drum, unspecified ear |
| H66.01 | Acute suppurative otitis media with spontaneous rupture of ear drum |
| H66.011 | Acute suppurative otitis media with spontaneous rupture of ear drum, right ear |
| H66.012 | Acute suppurative otitis media with spontaneous rupture of ear drum, left ear |
| H66.013 | Acute suppurative otitis media with spontaneous rupture of ear drum, bilateral |
| H66.014 | Acute suppurative otitis media with spontaneous rupture of ear drum, recurrent, right ear |
| H66.015 | Acute suppurative otitis media with spontaneous rupture of ear drum, recurrent, left ear |
| H66.016 | Acute suppurative otitis media with spontaneous rupture of ear drum, recurrent, bilateral |
| H66.017 | Acute suppurative otitis media with spontaneous rupture of ear drum, recurrent, unspecified ear |
| H66.019 | Acute suppurative otitis media with spontaneous rupture of ear drum, unspecified ear |
| H66.4 | Suppurative otitis media, unspecified |
| H66.40 | Suppurative otitis media, unspecified, unspecified ear |
| H66.41 | Suppurative otitis media, unspecified, right ear |
| H66.42 | Suppurative otitis media, unspecified, left ear |
| H66.43 | Suppurative otitis media, unspecified, bilateral |
| H66.9 | Otitis media, unspecified |
| H66.90 | Otitis media, unspecified, unspecified ear |
| H66.91 | Otitis media, unspecified, right ear |
| H66.92 | Otitis media, unspecified, left ear |
| H66.93 | Otitis media, unspecified, bilateral |
| Streptococcus pneumoniae bronchitis | |
| B95.3 | Streptococcus pneumoniae as the cause of diseases classified elsewhere |
| J20.2 | Acute bronchitis due to streptococcus |
| Tonsillitis due to streptococcus pyogenes | |
| J03.0 | Streptococcal tonsillitis |
| J03.00 | Acute streptococcal tonsillitis, unspecified |
| J03.01 | Acute recurrent streptococcal tonsillitis |
Formulary Reference Tool